Inderjit Mehmi

Clinical trials

• Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

  Site PI · Recruiting · Phase 2

  H. Lee Moffitt Cancer Center and Research Institute

  2024–2030
• Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

  Site PI · Recruiting · Phase 2

  NYU Langone Health

  2023–2028
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2022–2027
• Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

  Site PI · Unknown · Phase 1, Phase 2

  Taiga Biotechnologies, Inc.

  2021–2023